The Blood Profiling Atlas in Cancer (BloodPAC) consortium published generic protocols for analytical validation of tumor‑informed circulating tumor DNA (ctDNA) assays for minimal residual disease (MRD) in JCO Precision Oncology. The guidance covers limit of detection, limit of blank, accuracy, precision, specimen stability, and contrived‑to‑clinical sample comparability, and was developed by an industry, academic and regulatory working group. At the JP Morgan conference Myriad Genetics outlined an aggressive MRD commercialization roadmap, planning multiple tissue‑informed MRD launches across breast, renal, colorectal, endometrial, and ovarian cancers over 2026–2027. The combined push — a cross‑industry validation framework plus test vendors moving to market — could compress timelines for clinical adoption and payor engagement for tumor‑informed MRD testing. BloodPAC explicitly limited the protocols to MRD use cases and urged adaptation for assay‑specific designs.